AMENDMENTS TO THE SPECIFICATION:

Please amend the Abstract of the present application as follows:

The present invention is related to a method for the manufacture of a nucleic acid molecule comprising the steps of and compounds used therefore. The invention further provides a method of ligating, cleaving and immobilising oligonucleotides in order to manufacture nucleic acid molecules. The invention includes the steps wherein a first and second at least partially double-stranded oligonucleotides are ligated via their respective single-stranded overhangs. The ligation product may be immobilised to the surface via the modification that is provided on the first oligonucleotide. The immobilised ligation product is cleaved with the first type IIS restriction enzyme therein releasing an elongated oligonucleotide having an overhang. The elongated oligonucleotide may further be combined and ligated with a further at least partially double-stranded oligonucleotide to form a further ligated product that may be cleaved with a type IIS restriction enzyme releasing an elongated oligonucleotide having an overhang. The steps may be further repeated in various combinations.

a) providing a first at least partially double-stranded oligonucleotide which has a
modification allowing the oligonucleotide to be coupled to a surface, whereby the
oligonucleotide comprises a recognition site for a first type IIS restriction enzyme which cuts
outside its recognition site, and which oligonucleotide comprises a single-stranded overhang;
b) providing a second at least partially double-stranded oligonucleotide whereby the
oligonucleotide comprises a recognition site or a part thereof or a sequence which is
complementary thereto, for a second type HS restriction enzyme which cuts outside its
recognition site, and which second oligonucleotide comprises a single stranded overhang;
c) ligating the first and the second oligonucleotide via their overhangs generating a first
ligation product;
d) immobilising the first ligation product to the surface via the modification;
e) cutting the immobilised ligation product with the first type IIS restriction enzyme thus
releasing an elongated oligonucleotide having an overhang;
f) combining the elongated oligonucleotide with a further at least partially double-

Response to Non-Final Office Action mailed on April 16, 2008

Dykema docket no. 065477-0028

Electronically filed August 14, 2008